McCarthy Tétrault
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
Firms in Canada explain how they’ve adapted to a rule change in 2017 that has made advocacy skills more important in pharma disputes
Sponsored